Key points from article :
GlycanAge, a British biotech company focused on glycan biomarkers, has secured $4.2 million in seed funding to further develop their personalized preventative care solutions.
Glycans are complex sugars that play important roles in biological processes and change with disease; GlycanAge leverages this for early disease detection.
GlycanAge currently offers a biological age test and plans to use the funding to develop disease-specific diagnostic tools, establish regulatory pathways, and integrate artificial intelligence technology.
The company believes its glycan-based diagnostics have the potential to revolutionize preventative healthcare.
This research direction has been bolstered by significant grant support, including funds from Mubadala’s accelerator program HUB71 and an EU AI grant.
